


## PHARMACEUTICAL 2021



## CymaBay Therapeutics Inc. Rank 62 of 402





## PHARMACEUTICAL 2021



## CymaBay Therapeutics Inc. Rank 62 of 402



The relative strengths and weaknesses of CymaBay Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CymaBay Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 87% points. The greatest weakness of CymaBay Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 18% points.

The company's Economic Capital Ratio, given in the ranking table, is 236%, being 188% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	151,585
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,857
Liabilities, Non-Current	1,262
Other Assets	479
Other Compr. Net Income	-72
Other Expenses	-705
Other Liabilities	0
Other Net Income	1,616
Other Revenues	0
Property and Equipment	1,761
Research and Development	35,882
Selling, General and Administrative Expense	17,425

Output Variable	Value in 1000 USD
Assets	153,825
Liabilities	11,119
Expenses	52,602
Revenues	0
Stockholders Equity	142,706
Net Income	-50,986
Comprehensive Net Income	-51,022
Economic Capital Ratio	236%

